Stacking up the evidence

Not everything at ASCO is necessarily focused on solid tumours, there’s often some useful hints of progress on the hematologic malignancies front too.

Here we look at the building evidence for half a dozen such developments across myeloma, lymphomas, and acute leukemias.

To be clear this doesn’t mean they will all be of the good news type because sometimes early developments promise much and fizzle out over time.

This is the advantage of following compounds and technologies in new product development over time – you get to see them as they really are and not through the lens of rose tinted glasses….

BSB subscribers can read more on our latest update regarding immunotherapies not checkpoint blockade in hematologic malignancies  – you can log-in or click to access our ongoing ASCO21 coverage.

This content is restricted to subscribers

Posted by